SEC Form 4 · accession 0001439222-26-000120
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah Gheuens
Officer — Chief Medical Officer
Period of report
Aug 4, 2026
Accepted (ET)
Aug 6, 2026 · 4:13 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF2 | Aug 4, 2026 | S | 30,000 | $30.48 | D | 54,645 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $30.25 to $30.88. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.